cyc 202 has been researched along with Neoplasms in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (38.71) | 29.6817 |
| 2010's | 14 (45.16) | 24.3611 |
| 2020's | 5 (16.13) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Ibrahim, DA; Ismail, NS | 1 |
| Havlíček, L; Jorda, R; Kryštof, V; Pospíšil, T; Skrášková, Z; Strnad, M; Šturc, A; Vymětalová, L | 1 |
| Joshi, G; Kalra, S; Kumar, R; Munshi, A | 1 |
| Clarhaut, J; Compain, G; Galons, H; Oumata, N; Papot, S; Péraudeau, E; Renoux, B | 1 |
| Abdel-Aziz, HA; Abou-Seri, SM; Bonardi, A; Eldehna, WM; Elgazar, AA; Fahim, SH; Gratteri, P; Kryštof, V; Nocentini, A; Said, MA; Soliman, DH; Supuran, CT | 1 |
| Diab, S; Wang, S; Yu, M | 1 |
| Bian, J; Li, Z; Qin, Z; Tian, Y; Wang, J; Wu, T; Xu, C | 1 |
| Duan, Y; Han, J; Hou, S; Liao, C; Wang, Q; Xie, Z; Yang, X | 1 |
| Tritos, NA | 1 |
| Büküm, N; Flaxová, M; Hofman, J; Kouklíková, E; Louvarová, D; Novotná, E; Wsól, V | 1 |
| Cibis, H; Hess, D; Klempnauer, KH; Werwein, E | 1 |
| Albert, T; Antrecht, C; Baumgart, K; Eickhoff, J; Kelso, TW; Klebl, B; Lemcke, S; Meisterernst, M | 1 |
| El-Serafi, AT; Filipski, E; Hassan, M; Lévi, F; Sallam, H; Terelius, Y | 1 |
| Giordano, A; Morales, F | 1 |
| Becq, F; Dorothée, G; Gabdoulkhakova, AG; Galons, H; Gray, RD; Gueganton, L; Hall, B; Hery-Arnaud, G; Kulkarni, AB; Le Berre, R; Loaëc, N; Meijer, L; Mottier, D; Nelson, DJ; Norez, C; Nowak, E; Oumata, N; Prochazkova, M; Rault, G; Ravel, D; Riazanski, V; Rossi, AG; Witko-Sarsat, V | 1 |
| Dey, A; Lane, DP; Tergaonkar, V | 1 |
| Chen, J; Huang, XF | 1 |
| Aldoss, IT; Ganti, AK; Tashi, T | 1 |
| David-Pfeuty, T; Grierson, DS; Legraverend, M; Ludwig, O | 1 |
| Dvorák, Z; Popa, I; Starha, P; Trávnícek, Z; Vrzal, R | 1 |
| Armour, S; Chiao, J; Delbaldo, C; Diéras, V; Faivre, S; Frame, S; Gianella-Borradori, A; Girre, V; Green, SR; Laurence, V; Le Tourneau, C; Raymond, E; Vera, K | 1 |
| Jorda, R; Krystof, V; Paruch, K | 1 |
| Blake, D; Clarke, R; Cowan, A; Cummings, L; Fischer, PM; Lane, DP; MacKenzie, M; McClue, SJ; Melville, J; Stewart, K; Wang, S; Zhelev, N; Zheleva, D | 1 |
| Meijer, L; Raymond, E | 1 |
| Fischer, PM; Goddard, PM; Lane, DP; Nutley, BP; Raynaud, FI; Workman, P | 1 |
| Blagden, S; de Bono, J | 1 |
| Schmid, G; Wesierska-Gadek, J | 1 |
| Benson, C; Cassidy, J; Cruickshank, C; De Bono, J; Gianella-Borradori, A; Judson, I; Kaye, S; McGrath, H; O'Donnell, A; Raynaud, F; Twelves, C; Walton, M; White, J; Workman, P | 1 |
| Chen, XG; Zuo, MX | 1 |
| Cheok, CF; Dey, A; Lane, DP | 1 |
12 review(s) available for cyc 202 and Neoplasms
| Article | Year |
|---|---|
Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.
Topics: Amino Acid Sequence; Animals; Computer-Aided Design; Crystallography, X-Ray; Cyclin-Dependent Kinases; Drug Design; Humans; Models, Molecular; Neoplasms; Protein Conformation; Protein Kinase Inhibitors; Sequence Alignment | 2017 |
CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Humans; Neoplasms; Protein Kinase Inhibitors | 2020 |
Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.
Topics: Animals; Antineoplastic Agents; Chemistry, Pharmaceutical; Cyclin-Dependent Kinase 9; Drug Development; Humans; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Protein Structure, Secondary | 2020 |
Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts.
Topics: Antineoplastic Agents; Cell Cycle; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinases; Drug Discovery; Humans; Neoplasms; Protein Kinase Inhibitors | 2022 |
Overview of CDK9 as a target in cancer research.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cyclic N-Oxides; Cyclin-Dependent Kinase 9; Flavonoids; Humans; Indolizines; Molecular Targeted Therapy; Neoplasms; Oxazoles; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridinium Compounds; Roscovitine; Thiazoles; Urea | 2016 |
Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis.
Topics: Adaptive Immunity; Analgesics; Animals; Anti-Inflammatory Agents; Clinical Trials as Topic; Cystic Fibrosis; Humans; Immunity, Innate; Immunomodulation; Neoplasms; Pain; Purines; Roscovitine | 2016 |
Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Cyclin-Dependent Kinases; Drug Design; Humans; Neoplasm Proteins; Neoplasms; NF-kappa B; Phosphorylation; Purines; Roscovitine; Tumor Suppressor Protein p53 | 2008 |
Cyclin-dependent kinase inhibitors inspired by roscovitine: purine bioisosteres.
Topics: Antineoplastic Agents; Cyclin-Dependent Kinases; Drug Design; Heterocyclic Compounds; Humans; Neoplasms; Protein Kinase Inhibitors; Purines; Roscovitine; Structure-Activity Relationship | 2012 |
Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials.
Topics: Animals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Neoplasms; Oocytes; Phosphotransferases; Purines; Roscovitine; Starfish | 2003 |
Drugging cell cycle kinases in cancer therapy.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Binding Sites; Cyclin-Dependent Kinases; Flavonoids; Humans; Neoplasms; Oxazoles; Piperidines; Protein Kinase Inhibitors; Purines; Roscovitine; Staurosporine; Sulfonamides; Thiazoles | 2005 |
Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Proliferation; Clinical Trials as Topic; Cyclin-Dependent Kinase Inhibitor Proteins; Cyclin-Dependent Kinases; Drug Evaluation, Preclinical; Flavonoids; Gene Expression Regulation; Humans; Mutation; Neoplasms; Piperidines; Protein Kinase Inhibitors; Purines; Roscovitine; Transcription, Genetic; Tumor Suppressor Protein p53 | 2006 |
[Research on cyclin-dependent kinase inhibitors: state of the art and perspective].
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cyclin-Dependent Kinases; Cyclins; Flavonoids; Humans; Neoplasms; Piperidines; Purines; Roscovitine; Staurosporine | 2007 |
2 trial(s) available for cyc 202 and Neoplasms
| Article | Year |
|---|---|
Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Female; Humans; Male; Maximum Tolerated Dose; Metabolic Diseases; Middle Aged; Nausea; Neoplasms; Purines; Roscovitine; Vomiting | 2010 |
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Hyperglycemia; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Purines; Roscovitine; Treatment Outcome | 2007 |
17 other study(ies) available for cyc 202 and Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors.
Topics: Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Proliferation; Cyclin A; Cyclin D; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Drug Design; Enzyme Inhibitors; Humans; Models, Molecular; Neoplasms; Pyrimidines | 2011 |
5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; G2 Phase; Humans; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2016 |
A β-glucuronidase-responsive albumin-binding prodrug for potential selective kinase inhibitor-based cancer chemotherapy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Glucuronidase; Humans; Models, Molecular; Neoplasms; Prodrugs; Protein Binding; Protein Kinase Inhibitors; Serum Albumin, Human | 2018 |
Sulfonamide-based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: Design, synthesis, and in vitro biological evaluation.
Topics: Antineoplastic Agents; Azo Compounds; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; In Vitro Techniques; Molecular Docking Simulation; Molecular Structure; Neoplasms; Pyrazoles; Structure-Activity Relationship; Sulfonamides | 2020 |
New Hope for a Tumor-Directed Therapy for Cushing Disease.
Topics: Humans; Neoplasms; Pituitary ACTH Hypersecretion; Pituitary Diseases; Pituitary Gland; Roscovitine | 2023 |
Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment.
Topics: Aldo-Keto Reductase Family 1 Member C3; Anthracyclines; Antineoplastic Agents; Cloning, Molecular; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; HCT116 Cells; Hep G2 Cells; Humans; Neoplasms; Purines; Roscovitine | 2018 |
Activation of the oncogenic transcription factor B-Myb via multisite phosphorylation and prolyl cis/trans isomerization.
Topics: Carcinogenesis; Cell Cycle; Cell Cycle Proteins; Cyclin-Dependent Kinases; Gene Expression Regulation, Neoplastic; HeLa Cells; Hep G2 Cells; Humans; Mitosis; Neoplasms; NIMA-Interacting Peptidylprolyl Isomerase; Nocodazole; Peptidylprolyl Isomerase; Phosphorylation; Polo-Like Kinase 1; Protein Conformation; Protein Multimerization; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Roscovitine; Thymidine; Trans-Activators; Transcription, Genetic | 2019 |
Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; HEK293 Cells; HeLa Cells; Humans; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; RNA Polymerase II; RNA, Messenger; Roscovitine; Triazines | 2014 |
The effect of circadian rhythm on pharmacokinetics and metabolism of the Cdk inhibitor, roscovitine, in tumor mice model.
Topics: Animals; Antineoplastic Agents; Chronopharmacokinetics; Circadian Rhythm; Cyclin-Dependent Kinases; Male; Mice; Models, Animal; Neoplasms; Protein Kinase Inhibitors; Purines; Roscovitine | 2015 |
Activation of p53 for the treatment of cancer.
Topics: Antineoplastic Agents; Apoptosis; Cisplatin; Humans; Neoplasms; Phosphorylation; Purines; Roscovitine; Tumor Suppressor Protein p53 | 2009 |
Seliciclib in malignancies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclin-Dependent Kinases; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Models, Biological; Neoplasms; Purines; Roscovitine | 2009 |
Targeting the cell cycle and the PI3K pathway: a possible universal strategy to reactivate innate tumor suppressor programmes in cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Survival; Chromones; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; HeLa Cells; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Molecular Structure; Morpholines; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Purines; Roscovitine; Signal Transduction; Structure-Activity Relationship; Time Factors; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins | 2010 |
Roscovitine-based CDK inhibitors acting as N-donor ligands in the platinum(II) oxalato complexes: preparation, characterization and in vitro cytotoxicity.
Topics: Antineoplastic Agents; Cell Line; Cell Survival; Cells, Cultured; Cyclin-Dependent Kinases; Hepatocytes; Humans; Neoplasms; Organoplatinum Compounds; Oxalates; Protein Kinase Inhibitors; Purines; Roscovitine; Spectrum Analysis | 2010 |
In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine).
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Division; Colorectal Neoplasms; Cyclin E; Cyclin-Dependent Kinases; Enzyme Inhibitors; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Purines; Recombinant Proteins; Roscovitine; Transplantation, Heterologous; Tumor Cells, Cultured | 2002 |
Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis.
Topics: Animals; Area Under Curve; CDC2-CDC28 Kinases; Cyclin-Dependent Kinase 2; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Enzyme Inhibitors; Female; Free Radicals; Gene Library; Mice; Mice, Inbred BALB C; Models, Chemical; Neoplasms; Purines; Roscovitine; Structure-Activity Relationship; Time Factors | 2004 |
Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cyclin-Dependent Kinases; Drug Synergism; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Neoplasms; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Purines; Roscovitine; Tumor Suppressor Protein p53 | 2007 |